[go: up one dir, main page]

WO2008057634A3 - Polypeptides ayant des propriétés antiinflammatoires accrues et cytotoxiques réduites et procédés associés - Google Patents

Polypeptides ayant des propriétés antiinflammatoires accrues et cytotoxiques réduites et procédés associés Download PDF

Info

Publication number
WO2008057634A3
WO2008057634A3 PCT/US2007/072771 US2007072771W WO2008057634A3 WO 2008057634 A3 WO2008057634 A3 WO 2008057634A3 US 2007072771 W US2007072771 W US 2007072771W WO 2008057634 A3 WO2008057634 A3 WO 2008057634A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory
polypeptides
enhanced anti
cytotoxic properties
decreased cytotoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/072771
Other languages
English (en)
Other versions
WO2008057634A2 (fr
Inventor
Falk Nimmerjahn
Kaneko Yoshikatus
Jeffrey V Ravetch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/041791 external-priority patent/WO2007055916A2/fr
Priority claimed from PCT/US2007/008396 external-priority patent/WO2007117505A2/fr
Priority to EA200970416A priority Critical patent/EA200970416A1/ru
Priority to CA2666308A priority patent/CA2666308C/fr
Priority to US12/447,204 priority patent/US8470318B2/en
Priority to EP07812601A priority patent/EP2091969A4/fr
Priority to JP2009534723A priority patent/JP2010512306A/ja
Priority to CNA2007800397349A priority patent/CN101528774A/zh
Priority to MX2009004399A priority patent/MX2009004399A/es
Priority to AU2007317755A priority patent/AU2007317755A1/en
Application filed by Rockefeller University filed Critical Rockefeller University
Priority to US11/957,015 priority patent/US20080206246A1/en
Priority to US12/013,212 priority patent/US20090004179A1/en
Publication of WO2008057634A2 publication Critical patent/WO2008057634A2/fr
Publication of WO2008057634A3 publication Critical patent/WO2008057634A3/fr
Priority to IL197920A priority patent/IL197920A0/en
Anticipated expiration legal-status Critical
Priority to US13/336,199 priority patent/US20120134988A1/en
Priority to US13/896,070 priority patent/US20130273040A1/en
Priority to US14/624,483 priority patent/US20160176950A1/en
Priority to US15/288,764 priority patent/US20170088608A1/en
Priority to US15/629,056 priority patent/US20170283492A1/en
Priority to US15/629,119 priority patent/US20170320935A1/en
Priority to US16/145,688 priority patent/US20190031737A1/en
Priority to US16/245,053 priority patent/US20190127446A1/en
Priority to US17/121,622 priority patent/US20210101961A1/en
Priority to US17/535,507 priority patent/US20220162290A1/en
Priority to US18/618,981 priority patent/US20240279314A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un polypeptide contenant au moins une région IgG Fc, ladite région IgG Fc étant glycosylée avec au moins une fonction galactose reliée à une fonction acide sialique terminale respective par une liaison α 2, 6, et ledit polypeptide ayant une activité antiinflammatoire accrue en comparaison d'un anticorps non purifié.
PCT/US2007/072771 2005-11-07 2007-07-03 Polypeptides ayant des propriétés antiinflammatoires accrues et cytotoxiques réduites et procédés associés Ceased WO2008057634A2 (fr)

Priority Applications (22)

Application Number Priority Date Filing Date Title
AU2007317755A AU2007317755A1 (en) 2006-10-27 2007-07-03 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
CA2666308A CA2666308C (fr) 2006-10-26 2007-07-03 Polypeptides ayant des proprietes antiinflammatoires accrues et cytotoxiques reduites et procedes associes
MX2009004399A MX2009004399A (es) 2005-11-07 2007-07-03 Polipeptidos con propiedades antiinflamatorias aumentadas y citotoxicas reducidas y metodos relacionados.
US12/447,204 US8470318B2 (en) 2005-11-07 2007-07-03 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP07812601A EP2091969A4 (fr) 2006-10-27 2007-07-03 Polypeptides ayant des proprietes antiinflammatoires accrues et cytotoxiques reduites et procedes associes
JP2009534723A JP2010512306A (ja) 2006-10-27 2007-07-03 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
CNA2007800397349A CN101528774A (zh) 2006-10-26 2007-07-03 具有增强的抗炎性和降低的细胞毒性特性的多肽以及相关方法
EA200970416A EA200970416A1 (ru) 2005-11-07 2007-07-03 Полипептиды с усиленными противовоспалительными и сниженными цитотоксическими свойствами и способы, относящиеся к ним
US11/957,015 US20080206246A1 (en) 2006-04-05 2007-12-14 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US12/013,212 US20090004179A1 (en) 2005-11-07 2008-01-11 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
IL197920A IL197920A0 (en) 2006-10-27 2009-04-05 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US13/336,199 US20120134988A1 (en) 2005-11-07 2011-12-23 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US13/896,070 US20130273040A1 (en) 2006-04-05 2013-05-16 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US14/624,483 US20160176950A1 (en) 2006-04-05 2015-02-17 Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
US15/288,764 US20170088608A1 (en) 2005-11-07 2016-10-07 Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
US15/629,119 US20170320935A1 (en) 2005-11-07 2017-06-21 Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
US15/629,056 US20170283492A1 (en) 2005-11-07 2017-06-21 Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
US16/145,688 US20190031737A1 (en) 2005-11-07 2018-09-28 Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
US16/245,053 US20190127446A1 (en) 2005-11-07 2019-01-10 Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
US17/121,622 US20210101961A1 (en) 2005-11-07 2020-12-14 Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
US17/535,507 US20220162290A1 (en) 2005-11-07 2021-11-24 Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
US18/618,981 US20240279314A1 (en) 2005-11-07 2024-03-27 Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
USPCT/US06/41791 2006-10-26
PCT/US2006/041791 WO2007055916A2 (fr) 2005-11-07 2006-10-27 Reactifs, procedes et systemes pour la selection d'un anticorps cytotoxique ou d'une variante
PCT/US2007/008396 WO2007117505A2 (fr) 2006-04-05 2007-04-03 Polypeptides presentant des proprietes anti-inflammatoires accrues et des proprietes cytotoxiques reduites, et procedes coorespondants
USPCT/US07/08396 2007-04-03

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2006/041791 Continuation WO2007055916A2 (fr) 2005-11-07 2006-10-27 Reactifs, procedes et systemes pour la selection d'un anticorps cytotoxique ou d'une variante
PCT/US2006/041790 Continuation WO2008048277A2 (fr) 2005-10-27 2006-10-27 Aimants permanents Mn-Al nanostructurés, et procédés de fabrication de ceux-ci
PCT/US2007/008396 Continuation-In-Part WO2007117505A2 (fr) 2005-11-07 2007-04-03 Polypeptides presentant des proprietes anti-inflammatoires accrues et des proprietes cytotoxiques reduites, et procedes coorespondants

Related Child Applications (5)

Application Number Title Priority Date Filing Date
PCT/US2007/008396 Continuation-In-Part WO2007117505A2 (fr) 2005-11-07 2007-04-03 Polypeptides presentant des proprietes anti-inflammatoires accrues et des proprietes cytotoxiques reduites, et procedes coorespondants
PCT/US2007/008396 Continuation WO2007117505A2 (fr) 2005-11-07 2007-04-03 Polypeptides presentant des proprietes anti-inflammatoires accrues et des proprietes cytotoxiques reduites, et procedes coorespondants
US12/447,204 A-371-Of-International US8470318B2 (en) 2005-11-07 2007-07-03 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US11/957,015 Continuation-In-Part US20080206246A1 (en) 2005-11-07 2007-12-14 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US13/896,070 Continuation US20130273040A1 (en) 2005-11-07 2013-05-16 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods

Publications (2)

Publication Number Publication Date
WO2008057634A2 WO2008057634A2 (fr) 2008-05-15
WO2008057634A3 true WO2008057634A3 (fr) 2008-12-04

Family

ID=39367532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/072771 Ceased WO2008057634A2 (fr) 2005-11-07 2007-07-03 Polypeptides ayant des propriétés antiinflammatoires accrues et cytotoxiques réduites et procédés associés

Country Status (3)

Country Link
EP (1) EP2091969A4 (fr)
AU (1) AU2007317755A1 (fr)
WO (1) WO2008057634A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524470B2 (en) 2009-07-30 2013-09-03 Hoffman-La Roche, Inc. Enzymatic antibody processing
US9187564B2 (en) 2010-10-05 2015-11-17 Hoffmann-La Roche Inc. Antibodies against human TWEAK and uses thereof

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
JP6084761B2 (ja) 2006-04-05 2017-02-22 ザ ロックフェラー ユニバーシティー 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
CN101981200A (zh) 2008-03-27 2011-02-23 诺维信公司 从含木素纤维素材料产生发酵产物
US7846744B2 (en) 2008-04-22 2010-12-07 Ravetch Jeffrey V Methods of identifying anti-inflammatory compounds
EP2233499A1 (fr) 2009-03-26 2010-09-29 CSL Behring AG Composition d'anticorps avec Fab sialylation altérée
EP2233502A1 (fr) * 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Anticorps spécifiques à l'antigène syalilé pour le traitement ou prophylaxie des réactions immunitaires inflammatoires non désirables et leurs procédés de production
EP2427497B1 (fr) 2009-05-07 2016-12-07 Stallergenes Utilisation d'immunoglobulines igg1 et/ou de ligands du récepteur cd32 pour le traitement de maladies et manifestations inflammatoires par voie mucosale
US20130058917A1 (en) 2010-05-07 2013-03-07 Fabian Käsermann Antibody composition obtained by fractionation of plasma immunoglobulins affinity chromatography on a sambucus nigra affinity column
WO2012012590A2 (fr) 2010-07-23 2012-01-26 Novozymes A/S Procédés pour produire des produits de fermentation
EP2640483A1 (fr) * 2010-11-15 2013-09-25 Biogen Idec Inc. Enrichissement et concentration d'isoformes de produit choisis par liaison surchargée et chromatographie d'élution
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9650433B2 (en) 2011-05-20 2017-05-16 Momenta Pharmaceuticals, Inc. Modified glycoproteins
ES2548215T3 (es) 2011-10-05 2015-10-14 F. Hoffmann-La Roche Ag Proceso para la producción de anticuerpos de la glicoforma G1
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
EP4234577A3 (fr) 2012-04-25 2023-10-18 Momenta Pharmaceuticals, Inc. Glycoprotéines modifiées
US20150210753A1 (en) 2012-07-26 2015-07-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US20150252108A1 (en) * 2012-09-26 2015-09-10 Momenta Pharmaceuticals, Inc. Glycoprotein preparations
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2014149067A1 (fr) 2013-03-15 2014-09-25 Momenta Pharmaceuticals, Inc. Procédés se rapportant à des protéines de fusion fc-ctla4
WO2014186310A1 (fr) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Méthodes de traitement de la neurodégénérescence
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
EP3058084A4 (fr) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Glycoprotéines sialylées
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (fr) 2013-11-15 2015-05-21 Abbvie, Inc. Compositions de protéines de liaison génétiquement glycomodifiées
WO2019125846A1 (fr) 2017-12-19 2019-06-27 The Rockefeller University Variants de domaine fc de l'igg humaine à fonction d'effecteur améliorée

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164328A1 (en) * 2000-10-06 2002-11-07 Toyohide Shinkawa Process for purifying antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
ES2378272T3 (es) * 1999-04-15 2012-04-10 Crucell Holland B.V. Producción de proteína recombinante en una célula humana
AU2003303394B2 (en) * 2002-12-23 2009-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
CA2551916C (fr) * 2003-12-31 2014-04-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Proteine hybride fc-erythropoietine a pharmacocinetique amelioree
DK1896071T3 (en) * 2005-06-30 2015-05-26 Janssen Biotech Inc Methods and compositions with increased therapeutic activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164328A1 (en) * 2000-10-06 2002-11-07 Toyohide Shinkawa Process for purifying antibody

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP2091969A4 *
WEIKER S. ET AL.: "Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins", NATURE BIOTECHNOLOGY, vol. 17, no. 11, November 1999 (1999-11-01), pages 1116 - 1121, XP002203703 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524470B2 (en) 2009-07-30 2013-09-03 Hoffman-La Roche, Inc. Enzymatic antibody processing
US9187564B2 (en) 2010-10-05 2015-11-17 Hoffmann-La Roche Inc. Antibodies against human TWEAK and uses thereof

Also Published As

Publication number Publication date
EP2091969A4 (fr) 2010-05-12
AU2007317755A1 (en) 2008-05-15
EP2091969A2 (fr) 2009-08-26
WO2008057634A2 (fr) 2008-05-15

Similar Documents

Publication Publication Date Title
WO2008057634A3 (fr) Polypeptides ayant des propriétés antiinflammatoires accrues et cytotoxiques réduites et procédés associés
MX2009004399A (es) Polipeptidos con propiedades antiinflamatorias aumentadas y citotoxicas reducidas y metodos relacionados.
EA201070739A1 (ru) Полипептиды с усиленными противовоспалительными и сниженными цитотоксическими свойствами и связанные с ними способы
WO2007117505A3 (fr) Polypeptides presentant des proprietes anti-inflammatoires accrues et des proprietes cytotoxiques reduites, et procedes coorespondants
WO2006094192A3 (fr) Anticorps humanises l243
JO2824B1 (en) Antibody glycosylate in the changing region
WO2008008482A3 (fr) Polypeptides de liaison à br3 modifiés
WO2006074467A3 (fr) Facteur de stimulation de colonie de granulocytes glycopegylatees
WO2007005786A3 (fr) Procedes et compositions a effet therapeutique ameliore
WO2007134876A3 (fr) ANTICORPS D'AFFINITÉ ÉLEVÉE HUMAINS ET HUMANISÉS À FONCTION DE BLOCAGE ANTI-INTÉGRINE α5β1 AYANT UNE IMMUNOGÉNICITÉ RÉDUITE
WO2011028195A3 (fr) Compositions contenant et procédés faisant intervenir des acides aminés et polypeptides non naturels et utilisations de ceux-ci
WO2005012484A3 (fr) Conjugues anticorps-toxines
WO2008140603A3 (fr) MÉTHODES POUR LE TRAITEMENT DE MALADIE AU MOYEN D'IMMUNOGLOBULINES COMPRENANT DES RÉGIONS FC QUI PRÉSENTENT DES AFFINITÉS ALTÉRÉES POUR FCγR D'ACTIVATION ET FCγR D'INHIBITION
WO2008060780A3 (fr) Glycopeptides et sucres pégylés à liaison glycérol
EP2570434A3 (fr) Antagonistes de la neuropiline
WO2005003175A3 (fr) Anticorps d'aglycosyle anti-cd154 (ligand cd40) et utilisations correspondantes
WO2007079130A3 (fr) Acides aminés et polypeptides non naturels, compositions contenant ceux-ci, procédés mettant en jeu ceux-ci et utilisations de ceux-ci
WO2005055950A3 (fr) Facteur ix glycopegyle
EP2937361A3 (fr) Fc variants ayant une liaison altérée à FcRn
WO2006082184A3 (fr) Conjugues d'un polypeptide et d'un oligosaccharide
WO2008079995A3 (fr) Conjugué comprenant un peptide natriurétique et une région constante d'un anticorps
WO2007138199A3 (fr) Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
UA95284C2 (ru) Антитела к рецептору инсулинподобного фактора роста i и их применение
WO2008077956A3 (fr) Conjugués oligonucléotide-, protéine- et/ou peptide-polymère
WO2006014683A3 (fr) Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780039734.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07812601

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007317755

Country of ref document: AU

Ref document number: 1222/KOLNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 576001

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 197920

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2666308

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009534723

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2007317755

Country of ref document: AU

Date of ref document: 20070703

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/004399

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007812601

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200970416

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 12447204

Country of ref document: US